

MC 6.033 Streptococcus Viridans Group Susceptibility Reporting

	This procedure provides instruction and guidance for routine testing and selective and cascade susceptibility eporting on Streptococcus Viridans group.		
Principal and Clinical Significance			
Policy Statements	This procedure applies to Microbiologists who perform susceptibility testing.		
Special Safety Precautions	Microbiologists are subject to occupational risks associated with specimen handling. <u>Biohazard Containment</u> <u>Biohazardous Spills</u> <u>Safety in the Microbiology Laboratory</u> 		
Procedure	 Examples of organisms in the Streptococcus Viridans group include: Alpha Hemolytic Streptococcus Alpha Hemolytic Streptococcus, Viridans group Streptococcus anginosus Streptococcus conis Streptococcus constellatus Streptococcus gallolyticus Streptococcus gondonii Streptococcus gondonii Streptococcus mitis/oralis Streptococcus mitis/oralis Streptococcus parasanguinis Streptococcus salivarius Streptococcus salivarius Streptococcus salivarius Streptococcus salivarius Streptococcus salivarius Antibiotics appropriate for routine testing and reporting for Beta Hemolytic Streptococcus group include: Penicillin Ampicillin Ceftriaxone Cefotaxime Vancomycin Linezolid Levofloxacin Erythromycin Clindamycin Cefepime 		

•



- Ceftolozane-Tazobactam
- 3. Perform susceptibilities using Vitek cards AST-ST02, MicroScan MicroStrep or Kirby Bauer Method.
 - Vitek AST-ST02 will be the primary method of testing.
 - MicroScan MicroStrep and Kirby Bauer are back up if testing fails.
 - Do not perform testing on multiple methods to cover all the antibiotics. It is acceptable if cascaded antibiotics are not reported.
- 4. Vitek results will be accepted under the Online Results tab. Modifications will be under the **VITMIC** keyboard under the Susceptibility tab.
- 5. MicroScan MicroStrep will be entered manually under the **MMIC** keyboards under the Susceptibility tab.
- 6. Kirby Bauer results will be entered manually under the KB keyboards under the Susceptibility tab.

Selective Reporting	 Antibiotics will be reported in a specific order indicating the first and subsequent preferences of the Antimicrobial Stewardship Committee and Infectious Disease physicians 			
	 Antibiotics will be reported depending on the source, if the sample is a urine, non-urine or CSF source. 			
	3. There will be exceptions based on the method used for testing.			
	 4. For urine sources, 2 antibiotics will be reported routinely, in this order. 1. Ampicillin 2. Penicillin 			
	Figure 1 -Only AM and Pen are reported. All other antibiotics are in HIDE Organism #1 - STREPTOCOCCUS SPECIES, VIRIDANS GROUP			
	- VITMIC - S5 AM(0.25),P(0.12) HIDE CAX(1-S5),VA(1-S5),LZD(2-S5),LEVO(2-S5)			
	 For non-urine sources, including blood, 2 antibiotics will be reported routinely, in this order. 			
	1. Ampicillin 2. Penicillin			
	•			

- SS
 AM(0.25),P(0.12)


 HIDE
 CAX(1-SS),VA(1-SS),LZD(2-SS),CD(1-R),E(1-R),LEVO(2-SS)
- 6. For **CSF** sources, 2 antibiotics will be reported routinely, in this order.
 - 1. Ampicillin

VITMIC -

- 2. Penicillin
- Figure 3-Only Am and Pen are reported. All other antibiotics are in HIDE.

Organism #5 -	STREPTOCOCCUS ANGINOSUS GROUP
- VITMIC -	
SS	AM(0.25),P(0.12)
HIDE	CAX(1-SS),VA(1-SS),LZD(2-SS)





- If Ampicillin or Penicillin is $R \rightarrow$ report Ceftriaxone
- If Ceftriaxone is $R \rightarrow$ report Vancomycin

Figure 4- Example with resistance on a urine culture

Organism #1 - STRE	PTOCOCCUS SPECIES, VIRIDANS GROUP
- VITMIC -	
SS	VA(1)
R	AM(8),P(4),CAX(4)
HIDE	LZD(2-SS),LEVO(2-SS)

Figure 5-Example with resistance on a non-urine culture

Organism #2 - STR	EPTOCOCCUS INTERMEDIUS
- VITMIC -	
SS	VA(1)
R	AM(8),P(4),CAX(4)
HIDE	LZD(2-SS),CD(0.25-SS),E(0.25-SS),LEV0(2-SS)

- 3. All other antibiotics on the panel that are not part of the cascade are hidden. Do not release and report. Hidden antibiotics include:
 - o Erythromycin
 - o Clindamycin
 - Levofloxacin
 - o Linezolid
- 4. Requested antibiotics may be released with a provider request

Cascade Reporting- MicroScan	If resistance is encountered or ETEST performed, use the MMIC keyboard. Additional antibiotics will automatically be released.
Method	1. Enter results manually under the MMIC keyboard.
	2. Hidden antibiotics will be released when Fileis clicked. Results will be visible in

Results Summary.

Method: MicroScan MicroStrep – all sources

- If Ampicillin or Penicillin is $R \rightarrow$ report Ceftriaxone
- If Ceftriaxone is $R \rightarrow$ report Vancomycin



3. Click on File. Result will be un-hidden.

Figure 6-Example of resistance on a urine culture

Organism - STREPTOCOCCUS MUTANS #7	
- MMIC - (ZZO2)	
SS	VA(1)
R	AM(8),P(4),CAX(4)
HIDE	CEFE(4-R),LEVO(2-SS)

Figure 7 Example of resistance on a non-urine culture

Organism #4-	STREPTOCOCCUS MITIS/STREPTOCOCCUS ORALIS (STRAIN 2)
- MMIC -	
SS	VA(1)
R	AM(8),P(4),CAX(4)
HIDE	CEFE(1-SS),CD(0.25-SS),E(0.25-SS),LEVO(2-SS)

- 4. All other antibiotics on the panel that are not part of the cascade are hidden. Do not release and report. Hidden antibiotics include:
 - o Erythromycin
 - o Clindamycin
 - Cefepime
 - \circ Levofloxacin
- 5. Requested antibiotics may be released with a provider request.

Cascade Reporting-Kirby Bauer Method

- 1. Kirby Bauer method will not be very helpful, as Ampicillin and Penicillin do not have KB breakpoints.
- 2. If Vitek or MicroScan MicroStrep do not yield results:
 - Set up Penicillin Etest and result under MMIC keyboard.
 - If Penicillin is resistant, set up Vancomycin Etest and result under MMIC keyboard.
- 3. If KB method is used, enter all listed results manually under the **KB** keyboard.

Method: Kirby Bauer - all sources


- If Penicillin Etest is $R \rightarrow$ report Vancomycin
- 4. Click the check mark under SUP to remove from HIDE

igure 8 KB Keyboard					
Seyboard KB - KIRBY BAUER					
S H	O B Organism				
6 🗹 🗌	6 V STREPTOCOCCUS MITIS				
7	STREPTOCOCCU	JS SANGUIS I	I		
	✓ Suppress all				
D O I					
Drug Code	Drug Name	SUP	Result	Interpretation	
VA VA	Drug Name VANCOMYCIN		Result	Interpretation	
_	_	SUP		<pre>Interpretation <<od not="" report="">></od></pre>	
_	_		17		
VA	VANCOMYCIN		17 HIDE	< <do not="" report="">></do>	
VA	VANCOMYCIN		17 HIDE 15	< <do not="" report="">> RESISTANT</do>	
VA < <e>></e>	VANCOMYCIN		17 HIDE 15 HIDE	<pre><<d0 not="" report="">> RESISTANT <<d0 not="" report="">></d0></d0></pre>	



5.	Click on File	<u>F</u> ile	. Result will be un-hidden
----	---------------	--------------	----------------------------

Figure 9 Example with Penicillin resistant by Etest, KB set up for Vancomycin



- 6. All other antibiotics on the panel that are not part of the cascade are hidden. Do not release and report. Hidden antibiotics include:
 - Erythromycin
 - o Clindamycin
- 7. Requested antibiotics may be released with a provider request.

Method Performance Specifications	 Usually, only the Vitek card AST-ST02 will be required for testing Streptococcus Viridans Group. KB method with require Penicillin Etest. Set up penicillin Etest day of use QC. If Vancomycin Etest is performed, set up Vancomycin Etest day use QC.
-----------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Appendix Additional Tables and Flowcharts

Vitek

St	rep sp. Urine	
ANtibiotics	that are reported- Urine	
Sunquest code	Drug Name	
AM	Ampicillin	
Р	Penicillin	If Penicillin or Ampicillin R Report Ceftriaxone CAX
Hidden antibiotics		
CAX	Ceftriaxone	If Ceftriaxone R Report Vancomycin VA
VA	Vancomycin	
LZD	Linezolid	
LEVO	Levofloxacin	



Strep sp. Non-Urine		
Antibiotics that	at are reported- Non-urine	1
Sunquest code	Drug Name	
AM	Ampicillin	
Р	Penicillin	If Penicillin or Ampicillin R
Hie	dden antibiotics	Report Ceftriaxone CAX
CAX	Ceftriaxone	If Ceftriaxone R
VA	Vancomycin	Report Vancomycii
LZD	Linezolid	1
CD	Clindamycin	1
E	Erythromycin	1
LEVO	Levofloxacin	7

5	Strep sp. CSF	
Antibiotics that are reported- Non-urine		
Sunquest code	Drug Name	
AM	Ampicillin	
Р	Penicillin	If Penicillin or Ampicillin R Report Ceftriaxone CAX
Hidden antibiotics		★
CAX	Ceftriaxone	If Ceftriaxone R Report Vancomycin VA
VA	Vancomycin	Neport vancomycin VA
LZD	Linezolid]

MicroScan


Strep sp. Urine			
Antibiotics that are reported- Urine			
MICS (Abrv)	Sunquest code	Drug Name	
Am	AM	Ampicillin	
Р	Р	Penicillin	If Penicillin or Ampicillin R Report Ceftriaxone CAX
Hidden antibiotics			↓
Сах	CAX	Ceftriaxone	If Ceftriaxone R Report Vancomycin VA
Va	VA	Vancomycin	
Сре	CEFE	Cefepime]
Lvx	LEVO	Levofloxacin]




Strep sp. Non-Urine			
Antibio	tics that are report	ted- Non-Urine	
MICS (Abrv)	Sunquest code	Drug Name	
Am	AM	Ampicillin	
Р	Р	Penicillin	If Penicillin or Ampicillin R Report Ceftriaxone CAX
	Hidden antibio	↓	
Cax	CAX	Ceftriaxone	If Ceftriaxone R Report Vancomycin VA
Сре	CEFE	Cefepime	Report Valicomycin VA
Va	VA	Vancomycin	•
Cd	CD	Clindamycin]
E	E	Erythromycin]
Lvx	LEVO	Levofloxacin]

Strep sp. CSF	
Antibiotics that are reported- Non-Urine	
MICS (Abrv) Sunquest code Drug Name	
Am AM Ampicillin	
P P Penicillin F Penicillin or Ampicillin F Report Ceftriaxone C/	X I
Hidden antibiotics	_
Cax CAX Ceftriaxone If Ceftriaxone Report Vancomy	cin VA
Cpe CEFE Cefepime	
Va VA Vancomycin	

Kirby-Bauer







References

- 1. bioMerieux Vitek 2 AST-ST02 Streptococcus Susceptibility Card 046685-02 2021-08
- CLSI M100 edition 34 Performance Standards for Antimicrobial Susceptibility Testing 2024
 Beckman Coulter, Inc. MicroScan MicroStrep plus panel. August 2023. Brea, CA. www.beckmancoulter.com.

	Training Plan	Initial Competency Assessment
Training Plan/ Competency Assessment	 Employee must read the procedure. Employee will observe trainer performing the procedure. Employee will demonstrate the ability to perform procedure, record results and document corrective action after instruction by the trainer. 	1. Direct observation.

Historical

D.		-		J
- R (ec	:0	rc	

Version	Written/Revised by:	Effective Date:	Summary of Revisions
1	Susan DeMeyere	3/19/2025	Initial version